Method of differentiation of morula or inner cell mass cells and method of making lineage-defective embryonic stem cells

• US 20090104697A1
• Filed: 05/16/2008
• Published: 04/23/2009
• Est. Priority Date: 10/15/1999
• Status: Active Grant

• Current Assignee: Advanced Cell Technology Incorporated (Astellas Pharma Incorporated)
• Original Assignee: Advanced Cell Technology Incorporated (Astellas Pharma Incorporated)
• Inventors: West, Michael D., Lanza, Robert, Cibelli, Jose
• Granted Patent: US 8,753,884 B2
• Time in Patent Office: Days
• US Class Current: 435/377
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 13/02 of urine or of the urinary tract, e.g. urine acidifiers
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 19/04 for non-specific disorders of the connective tissue
• CPC Class Codes: A61P 21/04 for myasthenia gravis
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/14 for treating abnormal movements, e.g. chorea, dyskinesia
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 31/18 for HIV
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/02 Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
• CPC Class Codes: C12N 2510/00 Genetically modified cells
• CPC Class Codes: C12N 5/0606 Pluripotent embryonic cells, e.g. embryonic stem cells [ES] embryonic germ cells C12N5/0611, induced pluripotent stem cells C12N5/0696
• CPC Class Codes: C12N 5/16 Animal cells

Abstract

An improved method of producing differentiated progenitor cells comprising obtaining inner cell mass cells from a blastocyst and inducing differentiation of the inner cell mass cells to produce differentiated progenitor cells. The differentiated progenitor cells may be transfected such that there is an addition, deletion or alteration of a desired gene. The differentiated progenitor cells are useful in cell therapy and as a I source of cells for the production of tissues and organs for transplantation. Also provided is a method of producing a lineage-defective human embryonic stem cell.

Claims

1-35. -35. (canceled)

36. A method of producing differentiated cells, comprising:

i) obtaining morula-derived cells or inner cell mass cells from a blastocyst by mechanical and/or enzymatic means; and

ii) inducing differentiation of the morula-derived cells or inner cell mass cells to produce differentiated cells by addition of a differentiating agent or exposure to environmental factors.

37. The method according to claim 36 further comprising isolating said differentiated cells.

38. The method according to claim 36, wherein said morula-derived cells or inner cell mass cells are induced to differentiate in the absence of undifferentiated embryonic stem cells.

39. The method according to claim 36, wherein said blastocyst is produced by in vitro fertilization.

40. The method according to claim 36, wherein said blastocyst is a human blastocyst.

41. The method according to claim 36, wherein said blastocyst is produced from a nuclear transfer unit.

42. The method according to claim 41, wherein a desired DNA is inserted, removed or modified in said nuclear transfer unit, thereby resulting in the production of a genetically altered differentiated cell.

43. The method according to claim 36, wherein said inner cell mass cells are induced to differentiate in a flat adhesive environment.

44. The method according to claim 36, wherein said inner cell mass cells are induced to differentiate in a 3D adhesive environment.

45. The method according to claim 36, wherein said inner cell mass cells are induced to differentiate in a microgravity.

46. The method according to claim 36, wherein said inner cell mass cells are induced to differentiate by generation of teratomas in immunodeficient mice.

47. The method according to claim 36, wherein the differentiated cells are differentiated progenitor cells.

48. The method according to claim 47, wherein the differentiated progenitor cells are derived from mesoderm.

49. The method according to claim 47, wherein the differentiated progenitor cells are derived from ectoderm.

50. The method according to claim 47, wherein the differentiated progenitor cells are derived from endoderm.